DekaBank Deutsche Girozentrale’s Bicycle Therapeutics BCYC Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,000	Closed	-$801K	–	1137
2025 Q4	$801K	Hold	30,000	–	–	﹤0.01%	921
2025 Q3	$220K	Hold	30,000	–	–	﹤0.01%	1117
2025 Q2	$211K	Hold	30,000	–	–	﹤0.01%	1115
2025 Q1	$256K	Hold	30,000	–	–	﹤0.01%	1073
2024 Q4	$414K	Hold	30,000	–	–	﹤0.01%	1034
2024 Q3	$666K	Hold	30,000	–	–	﹤0.01%	953
2024 Q2	$582K	Hold	30,000	–	–	﹤0.01%	981
2024 Q1	$700K	Hold	30,000	–	–	﹤0.01%	941
2023 Q4	$537K	Hold	30,000	–	–	﹤0.01%	1020
2023 Q3	$584K	Hold	30,000	–	–	﹤0.01%	983
2023 Q2	$720K	Buy	30,000 +16,800	+127%	+$390K	﹤0.01%	949
2023 Q1	$275K	Hold	13,200	–	–	﹤0.01%	1140
2022 Q4	$375K	Hold	13,200	–	–	﹤0.01%	1101
2022 Q3	$300K	Hold	13,200	–	–	﹤0.01%	1153
2022 Q2	$214K	Hold	13,200	–	–	﹤0.01%	1173
2022 Q1	$562K	Buy	13,200 +1,200	+10%	+$56K	﹤0.01%	1040
2021 Q4	$675K	Buy	+12,000	New	+$662K	﹤0.01%	1030

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

GSK plc London $599M AUM

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DekaBank Deutsche Girozentrale's BCYC Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 30,000 shares — an estimated $801K sold.

DekaBank Deutsche Girozentrale first reported a position in BCYC in Q4 2021 and held it in 17 quarters. The position peaked at $801K in Q4 2025. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 30,000 Bicycle Therapeutics shares in Q1 2026, an estimated $801K.
DekaBank Deutsche Girozentrale first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 17 quarters.
DekaBank Deutsche Girozentrale's Bicycle Therapeutics position peaked at $801K in Q4 2025.
98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.